Infrequent IV infusions of zoledronate significantly reduce fracture risks in postmenopausal women, according to a decade-long study. Women receiving two doses within five years had a 44 per cent ...
Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as this ...